| Expression pattern: |
DN |
| Associated gene: |
acetyl-CoA carboxylase 1 (ACC1) |
| Associated microRNA: |
- |
| Biological function: |
suppresses PCa cell proliferation and tumor growth; promotes apoptosis; decreases S phase entry; inhibits de novo fatty acid synthesis; improves therapeutic response in CRPC and EnzR-CRPC xenografts when delivered by PSMA-targeted nanoparticles |
| Molecular mechanism: |
circUTRN is negatively regulated by the AR-repressive complex and EZH2/PRC2-dependent mechanisms; circUTRN binds ACC1 and impairs ACC1 polymerization through AMPK signaling-dependent and independent pathways, suppressing ACC1-catalyzed de novo fatty acid synthesis. |
| Biological pathway or process: |
proliferation (inhibits); apoptosis (promotes); cell cycle (inhibits); lipid metabolism (inhibits); AMPK (promotes); drug resistance (inhibits); other pathway/process (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; circRNA-seq; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; Northern Blot; FISH / smFISH; IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; ChIP / ChIP-seq; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; In Vivo Animal Model; H&E Staining; Oil Red O Staining; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis |
| Clinical significance: |
circUTRN is downregulated in human PCa tissues, dynamically changes during progression to CRPC, and is proposed as a potential therapeutic target and diagnostic/therapy-related molecule for treatment-resistant PCa. |
| Description: |
circUTRN is a UTRN-derived human circRNA that is downregulated in prostate cancer tissues and negatively regulated by AR/EZH2-mediated repression. It functions as a tumor-suppressive circRNA by binding ACC1, disrupting ACC1 polymerization and de novo fatty acid synthesis, thereby inhibiting proliferation and promoting apoptosis. PSMA-targeted nanoparticle delivery of circUTRN showed therapeutic benefit in CRPC and enzalutamide-resistant CRPC xenograft models. |
| Confidence score: |
0.8902 |